Bronchoscopy is the most important tool in diagnosing respiratory disorders. Diagnostic indications are numerous and range from bronchial wash or bronchoalveolar lavage, in case of pulmonary infiltrations, to transbronchial lung biopsies in peripheral solitary pulmonary nodules. Different techniques, such as peripheral endobronchial ultrasound probes, or different navigation systems facilitate diagnosis of peripheral pulmonary lesions. Furthermore, endobronchial-guided transbronchial needle aspiration gained increased significance for mediastinal staging in lung cancer patients. Bronchoscopy also offers many therapeutic modalities. In case of haemoptysis, cold saline lavage, instillation of topical vasoconstrictive agents, endobronchial airway blockade, laser therapy, argon plasma coagulation and electrocautery present useful tools. Another indication for therapeutic bronchoscopy is a central airway obstruction resulting from benign or malignant processes. Rapid symptom control can be achieved by laser-assisted resection, electrocautery and cryodebridement. Furthermore, the insertion of an airway stent re-establishes the patency of obstructed airways. Brachytherapy is another treatment option for malignant airway stenoses. Due to its delayed effects, brachytherapy should only be considered in respiratorily stable patients. Recently developed therapeutic modalities are endoscopic lung volume reduction in patients with chronic obstructive pulmonary disease and bronchial thermoplasty in patients with asthma.
Share this Article
Related Content In Lung Cancer
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer
touchREVIEWS in Oncology & Haematology. 2021;17(1):42-47 DOI: https://doi.org/10.17925/OHR.2021.17.1.42
Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has become the standard-of-care treatment in the USA and elsewhere for classical epidermal growth factor receptor […]
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
touchREVIEWS in Oncology & Haematology. 2021;17(1):36-41 DOI: https://doi.org/10.17925/OHR.2021.17.1.36
The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the treatment of patients without oncogenic drivers. Consequently, the lives of patients with NSCLC have significantly […]
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!